Alirocumab
Brand name: Praluent Pen
Rank #109 of 500 drugs by total cost
$165.6M
Total Cost
203,805
Total Claims
$165.6M
Total Cost
6,684
Prescribers
$813
Cost per Claim
15,940
Beneficiaries
310,818
30-Day Fills
$25K
Avg Cost/Provider
30
Avg Claims/Provider
About Alirocumab
Alirocumab (sold as Praluent Pen) was prescribed 203,805 times by 6,684 Medicare Part D providers in 2023, costing the program $165.6M. At $813 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 106 | Duloxetine Hcl (Duloxetine Hcl) | $167.7M | 5,106,690 |
| 107 | Sucroferric Oxyhydroxide (Velphoro) | $166.8M | 54,837 |
| 108 | Lifitegrast (Xiidra) | $166.6M | 149,269 |
| 109 | Alirocumab (Praluent Pen) | $165.6M | 203,805 |
| 110 | Pantoprazole Sodium (Pantoprazole Sodium) | $165.1M | 10,061,854 |
| 111 | Lenvatinib Mesylate (Lenvima) | $164.6M | 7,004 |
| 112 | Treprostinil (Tyvaso Dpi) | $158.9M | 6,704 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology